{"id":444,"date":"2021-04-02T18:20:46","date_gmt":"2021-04-02T16:20:46","guid":{"rendered":"http:\/\/asso-cpdis.com\/?p=444"},"modified":"2021-04-02T18:20:46","modified_gmt":"2021-04-02T16:20:46","slug":"jeudi-20-mai-18h-visio-conference-les-crispr-cas9-du-concept-genetique-jusquau-medicament","status":"publish","type":"post","link":"https:\/\/asso-cpdis.com\/index.php\/2021\/04\/02\/jeudi-20-mai-18h-visio-conference-les-crispr-cas9-du-concept-genetique-jusquau-medicament\/","title":{"rendered":"Jeudi 20 mai 18h Visio conf\u00e9rence : \u00ab\u00a0Les CRISPR CAS9 : Du concept g\u00e9n\u00e9tique jusqu&rsquo;au m\u00e9dicament\u00a0\u00bb"},"content":{"rendered":"<div class=\"\"><b class=\"\">Les CRISPR CAS9 : du concept g\u00e9n\u00e9tique au m\u00e9dicament !<\/b><\/div>\n<div>Visio conf\u00e9rence 18h-19H30<\/div>\n<div><\/div>\n<div class=\"\">Notre Orateur sera : <strong>\u00a0Mario AMENDOLA *<\/strong><\/div>\n<div>Head of Gene editing laboratory\u00a0\u00a0au GENETHON \u00e0 Evry<\/div>\n<div class=\"\"><\/div>\n<div>la r\u00e9union sera divis\u00e9e en 3 parties.<\/div>\n<div><\/div>\n<div class=\"\">Premi\u00e8re partie : Le concept scientifique des CRIPSR CAS9 , en r\u00e9sumant la d\u00e9couverte de Emmanuelle Charpentier et Jennifer DOUDNA<\/div>\n<div class=\"\">Et les pistes actuelles d\u2019application, notamment celles du GENETHON.<\/div>\n<div class=\"\">Questions<\/div>\n<div class=\"\"><\/div>\n<div class=\"\">Deuxi\u00e8me partie : Etat des essais cliniques actuels d\u00e9montrant la preuve du concept.<\/div>\n<div class=\"\">Questions<\/div>\n<div class=\"\"><\/div>\n<div class=\"\">Troisi\u00e8me partie<\/div>\n<div class=\"\">Avenir des CRISPR CAS 9 : Quels m\u00e9dicaments pour quelles maladies ?<\/div>\n<div class=\"\">Questions<\/div>\n<div><\/div>\n<div>\n<div class=\"\"><i class=\"\">* Mario AMENDOLA dirige un groupe de recherche chez G\u00e9n\u00e9thon qui travaille sur le d\u00e9veloppement de nouveaux outils de transfert de g\u00e8ne et d&rsquo;\u00e9dition du g\u00e9nome et leur application pour le traitement des troubles g\u00e9n\u00e9tiques. Il a obtenu son dipl\u00f4me en Biotechnologie m\u00e9dicale \u00e0 l&rsquo;Universit\u00e9 de Turin (Italie) et son doctorat en m\u00e9decine mol\u00e9culaire au TIGET (Institut San Raffaele, Milan, Italie). Apr\u00e8s un post-doctorat au Netherlands Cancer Institute (Amsterdam), il a rejoint G\u00e9n\u00e9thon en 2015 et l&rsquo;INSERM en 2017. Ses recherches se sont concentr\u00e9es sur le d\u00e9veloppement de nouveaux outils de th\u00e9rapie g\u00e9nique et de transfert, utilisant l&rsquo;\u00e9dition g\u00e9nomique CRISPR pour la th\u00e9rapie g\u00e9nique des cellules souches h\u00e9matopo\u00ef\u00e9tiques et comprendre la dynamique de la chromatine, l&rsquo;expression des g\u00e8nes et les microARN.<\/i><\/div>\n<div class=\"\"><i class=\"\">\u00a0<\/i><\/div>\n<div class=\"\"><i class=\"\">Il \u00a0a contribu\u00e9 \u00e0 21 articles de recherche dans des revues scientifiques internationales et a re\u00e7u le prix d&rsquo;excellence en recherche de l&rsquo;American Society of Gene &amp; Cell Therapy (ASGCT).<\/i><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Les CRISPR CAS9 : du concept g\u00e9n\u00e9tique au m\u00e9dicament ! Visio conf\u00e9rence 18h-19H30 Notre Orateur sera : \u00a0Mario AMENDOLA * Head of Gene editing laboratory\u00a0\u00a0au GENETHON \u00e0 Evry la r\u00e9union sera divis\u00e9e en 3 parties. Premi\u00e8re partie : Le concept scientifique des CRIPSR CAS9 , en r\u00e9sumant la d\u00e9couverte de Emmanuelle Charpentier et Jennifer DOUDNA [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"class_list":["post-444","post","type-post","status-publish","format-standard","hentry","category-8"],"_links":{"self":[{"href":"https:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/posts\/444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/comments?post=444"}],"version-history":[{"count":1,"href":"https:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/posts\/444\/revisions"}],"predecessor-version":[{"id":445,"href":"https:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/posts\/444\/revisions\/445"}],"wp:attachment":[{"href":"https:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/media?parent=444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/categories?post=444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/tags?post=444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}